As described in an NCI Media Availability, early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will…
A documentary film where the title says it all, except… They are housemates and were diagnosed in the same month.
As with last fall’s group meeting, you can install our meeting app on your smart phone (Android or Apple), or you can simply use the online version in…
Invasive cancers typically evade immune surveillance through profound local and systemic immunosuppression, preventing their elimination or control. Targeting immune interventions to prevent or intercept premalignant…
Pilot studies can answer questions about whether a given trial design is feasible within the bounds of the National Clinical Trials Network and/or the NCI…
In recent years, community sites – specifically within the NCI Community Oncology Research Program (NCORP) – have accounted for about one-half of all SWOG-credited trial…
1. Disease Related Criteria Participant must have histologic diagnosis of prostate adenocarcinoma.Participant must have high or very high-risk disease defined by at least one of…
Clinical Trial Summary (S2210) What is the purpose of this clinical trial? This trial tests treatment for prostate cancer that is at high risk of…
Continuing that noble tradition, the newest Hope program is the Frank and Linda Meyskens Annual Endowed Lectureship on Advances in Cancer Prevention, which will sponsor…
